Pulmonx CORP Schedule 13G passive stakes

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed a Schedule 13G detailing their beneficial ownership of Pulmonx Corp. common stock.

The Vanguard Group reported a 0% beneficial ownership in Pulmonx Corp following an internal realignment, indicating a full divestment of its previously held stake.

PRIMECAP Management Co. reports a 12.16% beneficial ownership stake in Pulmonx Corporation, holding 4,956,691 shares as an investment adviser.

FMR LLC and Abigail P. Johnson have filed an amendment to their Schedule 13G, disclosing a 0.2% beneficial ownership in Pulmonx Corporation's common stock as of October 31, 2025.

FMR LLC and Abigail P. Johnson have reported a 5.4% beneficial ownership stake in Pulmonx Corp's common stock as of August 29, 2025.

FMR LLC and Abigail P. Johnson have disclosed a 10.6% beneficial ownership stake in Pulmonx Corp common stock as of June 30, 2025.

PRIMECAP Management Co/CA/ has filed an amended Schedule 13G, revealing a beneficial ownership of 13.61% in Pulmonx Corporation, totaling 5,414,761 shares as of March 31, 2025.

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have jointly filed an amended Schedule 13G, disclosing a beneficial ownership of 13.6% of Pulmonx Corp's common stock as of March 31, 2025.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed an amended Schedule 13G, revealing beneficial ownership of 8.5% of Pulmonx Corp's common stock as of March 31, 2025.

BlackRock, Inc. has filed an Amendment No. 3 to Schedule 13G, revealing a 6.8% beneficial ownership stake in Pulmonx Corp's common stock as of March 31, 2025.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed an amended Schedule 13G, detailing their beneficial ownership of 7.5% of Pulmonx Corp's common stock as of December 31, 2024.